AcadeMab Biomedical Inc.
National Biotechnology Research Park (Resident company)
Pharmaceutical, Biologics, Academia
AcadeMab Biomedical Inc. established in 2020.
．Have competitive antibody drug research and development technology platform.
．Independently develop new antibody drugs.
．Become a world-class antibody new drug research and development company.
Epithelial cell adhesion molecule (EpCAM) is highly expressed on the surface of many different kinds solid tumor which has the potential to become the target of cancer treatment. Our team developed Anti-EpCAM humanized antibody (AM-928) which is able to directly induce cancer cell apoptosis- and inhibit cancer stem cell growth. It has been proven to have obvious treatment in animal models of head and neck and colorectal cancer, effectively, making AM-928 an unmet medical need for head and neck and colorectal cancer treatment. The combination of AM-928 with Atezolizumab, an anti-PD-L1 antibody, almost completely eliminated tumors. The AM-928 antibody has been patented in many countries. In order to meet the needs of personalized medicine for anti-EpCAM precision medicine, EpCAM companion diagnostic reagents and molecular imaging are being developed.
Academab has established a fully human phage-displayed antibody library, which can efficiently select high specific and affinity antibodies. Combination of the high specificity and sensitivity anti-M13 antibody, a comprehensive antibody standardized screening technology also has been set up for one-stop antibody selection platform.